Zogenix, Inc. (NASDAQ:ZGNX) Q3 2019 Earnings Conference Call - Final Transcript

Nov 07, 2019 • 04:30 pm ET

Previous

Zogenix, Inc. (NASDAQ:ZGNX) Q3 2019 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Executive
Michael P. Smith

countries in Europe in the coming years. The net loss for the quarter ended September 30 2019 was $290.5 million or $6.75 per share and this compares with a net loss of $42.3 million or $1.08 per share in the third quarter ended September 30 2018. Again keeping in mind that the recorded $249.5 million in-process R&D expense related to the acquisition of Modis and MT1621 is the primary component of those loss amounts. In the first nine months of 2019 net loss was $363.4 million or a net loss of $8.54 per share compared with a net loss of $101.5 million or a net loss of $2.78 per share in the nine months ended September 30 in the prior year with again $249.5 million in-process R&D charge related to Modis being the primary factor in the amount of the loss. We ended the third quarter with cash cash equivalents and marketable securities total $255 million following the use of $175.5 million for the Modis acquisition which occurred on September 6 2019. We remain well capitalized and positioned to execute on our strategic plan to bring FINTEPLA to market as a potential new treatment option for Dravet syndrome and LGS patients and their family and have successfully expanded our late-stage pipeline through the acquisition of Modis and MT1621.

I'll now turn the call over to the operator to begin the Q&A session. Operator can you please provide the instructions?